Healthcare - Biotechnology - NASDAQ - US
$ 3.19
0.315 %
$ 56.7 M
Market Cap
-0.44
P/E
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc.[ Read More ]
The intrinsic value of one BIVI stock under the base case scenario is HIDDEN Compared to the current market price of 3.19 USD, BioVie Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BIVI
FINANCIALS
0
REVENUE
-32.2 M
OPERATING INCOME
-32.1 M
NET INCOME
-27.9 M
OPERATING CASH FLOW
14.5 M
INVESTING CASH FLOW
17.8 M
FINANCING CASH FLOW
0
REVENUE
-4.12 M
OPERATING INCOME
-4.15 M
NET INCOME
-3.58 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
-241 K
FINANCING CASH FLOW
Balance Sheet Decomposition
BioVie Inc.
| Current Assets | 24 M |
| Cash & Short-Term Investments | 23.8 M |
| Receivables | 0 |
| Other Current Assets | 204 K |
| Non-Current Assets | 1.16 M |
| Long-Term Investments | 0 |
| PP&E | 407 K |
| Other Non-Current Assets | 753 K |
| Current Liabilities | 9.35 M |
| Accounts Payable | 3.59 M |
| Short-Term Debt | 5.76 M |
| Other Current Liabilities | 3.77 K |
| Non-Current Liabilities | 350 K |
| Long-Term Debt | 350 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
BioVie Inc.
| Revenue | 0 |
| Cost Of Revenue | 229 K |
| Gross Profit | -229 K |
| Operating Expenses | 32 M |
| Operating Income | -32.2 M |
| Other Expenses | -59.1 K |
| Net Income | -32.1 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-207.15%
ROE
-127.42%
ROA
-151.74%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
BioVie Inc.
| Net Income | -32.1 M |
| Depreciation & Amortization | 229 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 4.66 M |
| Change in Working Capital | -86.8 K |
| Others | -714 K |
| Free Cash Flow | -27.9 M |
Wall Street Analysts Price Targets
BioVie Inc.
BIVI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
4.23%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
BioVie Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
128 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
17.5 K USD 1
6-9 MONTHS
17.8 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
8 months ago
Mar 04, 2024
|
Bought 10 K USD
|
DO CUONG V
President & CEO |
+ 10000
|
1 USD |
|
8 months ago
Mar 04, 2024
|
Bought 7.5 K USD
|
DO CUONG V
President & CEO |
+ 5000
|
1.5 USD |
|
11 months ago
Dec 01, 2023
|
Sell 128 K USD
|
GORLIN STEVE
Director |
- 75680
|
1.69 USD |
|
11 months ago
Nov 30, 2023
|
Bought 17.8 K USD
|
DO CUONG V
President & CEO |
+ 10000
|
1.78 USD |
|
1 year ago
Sep 05, 2023
|
Sell 26.1 K USD
|
GORLIN STEVE
Director |
- 8560
|
3.05 USD |
|
1 year ago
Aug 22, 2023
|
Sell 37.8 K USD
|
BERMAN RICHARD J
Director |
- 10805
|
3.5009 USD |
|
1 year ago
May 22, 2023
|
Sell 32.5 K USD
|
BERMAN RICHARD J
Director |
- 5000
|
6.5012 USD |
|
1 year ago
Jun 07, 2023
|
Sell 34.8 K USD
|
BERMAN RICHARD J
Director |
- 5984
|
5.8125 USD |
|
1 year ago
Mar 27, 2023
|
Sell 28.7 K USD
|
BERMAN RICHARD J
Director |
- 3371
|
8.517 USD |
|
1 year ago
Mar 28, 2023
|
Sell 42.6 K USD
|
BERMAN RICHARD J
Director |
- 5000
|
8.5215 USD |
|
1 year ago
Mar 28, 2023
|
Sell 22.3 K USD
|
BERMAN RICHARD J
Director |
- 2613
|
8.52 USD |
|
6 years ago
Jul 03, 2018
|
Bought 3.85 M USD
|
PEIZER TERREN S
director, 10 percent owner: |
+ 1713331
|
2.25 USD |
|
6 years ago
Jul 03, 2018
|
Bought 0 USD
|
PEIZER TERREN S
director, 10 percent owner: |
+ 1600000
|
0 USD |
|
2 years ago
Dec 07, 2021
|
Bought 10.8 K USD
|
KIM JOANNE WENDY
CFO |
+ 2000
|
5.399 USD |
|
4 years ago
Nov 03, 2020
|
Bought 19.3 K USD
|
GORLIN STEVE
Director |
+ 2430
|
7.95 USD |
|
4 years ago
Oct 30, 2020
|
Bought 20.5 K USD
|
GORLIN STEVE
Director |
+ 2570
|
7.97 USD |
|
4 years ago
Oct 21, 2020
|
Bought 46 K USD
|
GORLIN STEVE
Director |
+ 5000
|
9.19 USD |
|
4 years ago
Oct 15, 2020
|
Bought 50 K USD
|
GORLIN STEVE
Director |
+ 5000
|
10.01 USD |
|
4 years ago
Oct 15, 2020
|
Bought 50.5 K USD
|
GORLIN STEVE
Director |
+ 5000
|
10.1 USD |
|
4 years ago
Oct 15, 2020
|
Bought 40.8 K USD
|
GORLIN STEVE
Director |
+ 4000
|
10.19 USD |
|
4 years ago
Oct 15, 2020
|
Bought 10.2 K USD
|
GORLIN STEVE
Director |
+ 1000
|
10.18 USD |
|
4 years ago
Oct 15, 2020
|
Bought 1.03 K USD
|
GORLIN STEVE
Director |
+ 100
|
10.27 USD |
|
4 years ago
Oct 09, 2020
|
Bought 2.71 K USD
|
GORLIN STEVE
Director |
+ 282
|
9.61 USD |
|
4 years ago
Oct 07, 2020
|
Bought 44.4 K USD
|
GORLIN STEVE
Director |
+ 4718
|
9.42 USD |
|
4 years ago
Sep 22, 2020
|
Bought 150 K USD
|
GORLIN STEVE
Director |
+ 15000
|
10 USD |
7. News
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.
globenewswire.com
- 2 weeks ago
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.
globenewswire.com
- 2 weeks ago
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.
globenewswire.com
- 3 weeks ago
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses.
globenewswire.com
- 3 weeks ago
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARSON CITY, Nev., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share.
globenewswire.com
- 3 weeks ago
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share, resulting in total gross proceeds of $6,664,500, before deducting the placement agent's fees and offering expenses.
globenewswire.com
- 3 weeks ago
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets
globenewswire.com
- 1 month ago
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET).
accesswire.com
- 1 month ago
BioVie Inc. Announces Closing of Public Offering
CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of a previously announced best efforts public offering of 1,360,800 shares of its common stock, pre-funded warrants to purchase 600,000 shares of its common stock (“Pre-funded Warrants”) and warrants to purchase up to 1,960,800 shares of common stock (the "Common Warrants") at a combined public offering price of $1.53 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
globenewswire.com
- 1 month ago
Crude Oil Gains Over 1%; BioVie Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.
benzinga.com
- 1 month ago
BioVie Inc. Announces Pricing of Public Offering
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions.
globenewswire.com
- 1 month ago
BioVie Inc. Announces Proposed Public Offering
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying common stock purchase warrants in a best efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) and accompanying common stock purchase warrants are to be sold by the Company.
globenewswire.com
- 1 month ago
8. Profile Summary
BioVie Inc. BIVI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 56.7 M
Dividend Yield
4.23%
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Contact
680 West Nye Lane, Carson City, NV, 89703
https://bioviepharma.com
IPO Date
Sept. 18, 2020
Employees
14
Officers
Mr. Cuong Viet Do M.B.A.
President, Chief Executive Officer & Director
Ms. Joanne Wendy Kim CPA
Chief Financial Officer, Treasurer & Corporate Secretary
Dr. Christopher L. Reading Ph.D.
Senior Vice President of Alzheimer's Disease Program
Dr. Joseph M. Palumbo M.D.
Executive Vice President of R&D and Chief Medical Officer
Dr. Penelope Markham Ph.D.
Senior Vice President of Liver Disease Program
Mr. Clarence N. Ahlem
Senior Vice President of Operations
Ms. Denise Smith
Senior Vice President of Manufacturing & Development